<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<title>Антибиотики и антимикробная терапия :: Антибиотики и антимикробная терапия</title><meta name="KEYWORDS" content="антибиотик, лекарство, препарат, профилактика, лечение, антимикробная терапия, химиотерапия, резистентность, фармакоэпидемиология, фармакоэкономика, инфекция, вирус, бактерия"><meta name="DESCRIPTION" content="Антибиотики и антимикробная терапия"><meta name="resource-type" content="document"><meta http-equiv="expires" content="0"><meta name="author" content="Антибиотики и антимикробная терапия"><meta name="copyright" content="Copyright (c) 2001-2003 Антибиотики и антимикробная терапия"><meta name="distribution" content="Global"><meta name="rating" content="General"><link rel="StyleSheet" href="themes/Sandy/style/styleNN.css" type="text/css">
<style type="text/css">@import url("themes/Sandy/style/style.css"); </style>
<html>
<body>
<table align="center" border="0"><tr><td><center><b>Antimicrobial Resistance in Russia</b><br>Nosocomial pathogens<br><br><table width="640" cellspacing="1" cellpadding="0" border="0"><tr><td><hr><table border="0" width="640" cellpadding="20" cellspacing="1"><tr><td><!--
<INFO>Antimicrobial resistance in Russia</INFO>
<TITLE>Antimicrobial resistance in Russia: Nosocomial pathogens</TITLE>
<DESCRIPTION>Antimicrobial resistance in Russia. Nosocomial pathogens</DESCRIPTION>
<KEYWORDS>antimicrobial resistance, nosocomial pathogens, S.aureus, staphylococci, Enterococcus spp., Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter</KEYWORDS>
-->

<a href="index.php-29.html?doc=71">Antimicrobial Resistance</a> :: <a href="index.php-216.html?doc=73">Antimicrobial resistance in Russia</a> : Nosocomial pathogens<br>

<h2 class="c">Antimicrobial Resistance in Russia</h2>
<h3 class="c">Nosocomial pathogens</h3>

<ul class="txt">
<li><a href="#saureus"><i>S.aureus</i> and coagulase-negative staphylococci (CNS)</a></li>
<li><a href="#enterococcus"><i>Enterococcus</i> spp.</a></li>
<li><a href="#enterobacter">The <i>Enterobacteriaceae</i> family</a></li>
<li><a href="#paeruginosa"><i>Pseudomonas aeruginosa</i></a></li>
<li><a href="#acinetobacter"><i>Acinetobacter</i> spp.</a></li>
</ul><br>

<a name="saureus"></a><br>
<h4><i>S.aureus</i> and coagulase-negative staphylococci (CNS)</h4>

<p class="aj">In multicenter survey of staphylococci susceptibility in Moscow and St-Petersburg (1998) considerable differences in MRSA prevalence between some hospitals were revealed. The resistance to oxacillin was more frequent in CNS (0-65.9%) than among <i>S.aureus</i> (0-40%). Generally in Moscow the rate of MRSA was 33.4% and 4.1% in St-Petersburg.</p>
<p class="aj">All staphylococci resistant to oxacillin retained susceptible to vancomycin. Susceptibility rates of MRSA to fusidic acid, rifampin and ciprofloxacin were 95%, 84% and 70%, respectively (as compared with 80%, 85% and 61% for CNS).</p>
<p class="aj">Results of multicenter study of <i>S.aureus</i> resistance in Russia (&laquo;STENT&raquo;) performed in 2001 are shown in the <a href="#fig7">Figure&nbsp;7</a>.</p>

<a name="fig7"></a>
<table cellpadding="5" cellspacing="1" border="0" align="center"><tr><td>
<div align="center"><img src="modules/subjects/pages/eng/ar/images/arrus7en.gif" width="469" height="278" alt=""></div>
<p><b>Figure 7.</b>	Resistance (%) of <i>S.aureus</i> nosocomial strains (STENT, 2001)</p>
<p class="t8"><b>Abbreviations:</b><br> VA - vancomycin; LNZ - linezolid; SXT - co-trimoxazole; RIF - rifampin;<br> LVX - levofloxacin; CD - clindamycin; OX - oxacillin; GM - gentamicin;<br> TET - tetracycline; EM - erythromycin; CL - chloramphenicol.</p><br>
</td></tr></table>

<a name="enterococcus"></a><br>
<h4><i>Enterococcus</i> spp.</h4>

<p class="aj">Sixteen percent of <i>E.faecalis</i> strains resistant to ampicillin were revealed in survey conducted in Moscow and St-Petersburg in 1995-1996, and considerable variations of resistance frequency were observed between hospitals. Level of resistance to strepromycin was 44% and 25% to gentamicin. Neither intermediate nor resistant to vancomycin strains were observed. Unlike <i>E.faecalis</i> 75% of <i>E.faecium</i> strains were resistant to ampicillin, when its susceptibility to other antimicrobials didn't differ noticeably.</p>
<p class="aj">With epidemiological purpose susceptibility testing of enterococci strains isolated from feces of premature newborn was conducted. Results of antimicrobial activity in vitro are presented in <a href="#table8">Table&nbsp;8</a>.</p>
<p class="aj">Generally <i>E.faecium</i> demonstrated higher resistance rate to antimicrobials tested with the exception of vancomycin, which activity was equal to all enterococci, and quinopristin/dalfopristin (3%&nbsp;resistant isolates among <i>E.faecium</i> against 15% among <i>E.faecalis</i>). Only 3% of <i>E.faecalis</i> were resistant to ampicillin comparing with 77% of <i>E.faecium</i>. The majority of <i>E.faecium</i> strains showed high level of resistance to aminoglycosides (64% to gentamicin and 56% to streptomycin).</p>
<p class="aj">A&nbsp;total of 2664 isolates were tested during the multicenter prospective study of antimicrobial resistance of nosocomial gram-negative pathogens. It was performed in 28 ICUs of 15 cities of Russia in 1997-1999 <nobr>(&laquo;NPRS-3&raquo;)</nobr> (see <a href="#table9">Table&nbsp;9</a> and <a href="#fig9">Figure&nbsp;9</a>).</p>

<a name="table8"></a><br>
<p><b>Table 8.</b> Resistance (%) of <i>Enterococcus</i> spp. in premature newborns (Smolensk, 1995-1996).</p>
<table class="brd" cellpadding="5" cellspacing="1" border="0" width="100%">
<tr class="bkg"><th class="txc">Antimicrobial</th><th class="txc"><i>E.faecalis</i> (N=33)</th><th class="txc"><i>E.faecium</i> (N=61)</th></tr>
<tr class="bkg"><td class="txt">Ampicillin</td><td class="txc">3</td><td class="txc">77</td></tr>
<tr class="bkg"><td class="txt">Gentamicin</td><td class="txc">0</td><td class="txc">64</td></tr>
<tr class="bkg"><td class="txt">Streptomycin</td><td class="txc">3</td><td class="txc">56</td></tr>
<tr class="bkg"><td class="txt">Vancomycin</td><td class="txc">&nbsp; 9 *</td><td class="txc">&nbsp; 10 *</td></tr>
<tr class="bkg"><td class="txt">Chloramphenicol</td><td class="txc">39</td><td class="txc">54</td></tr>
<tr class="bkg"><td class="txt">Rifampicin</td><td class="txc">88</td><td class="txc">93</td></tr>
<tr class="bkg"><td class="txt">Quinupristin/Dalfopristin</td><td class="txc">15</td><td class="txc">3</td></tr>
</table>
<p>* Intermediate strains</p>

<a name="enterobacter"></a><br>
<h4>The <i>Enterobacteriaceae</i> family</h4>

<p class="aj">The resistance of <i>Enterobacteriaceae</i> family varied widely among different hospitals, reflecting the antibiotic policy.</p>
<p class="aj"><i>E.coli</i> strains manifested the highest resistance rates to ampicillin, piperacillin, cefuroxime. The most active against <i>E.coli</i> was imipenem, which was a subject for 100% susceptibility of <i>E.coli</i> strains. High activity was represented by piperacillin/tazobactam (6.3% resistance), III&nbsp;generation cefalosporins: ceftazidime (7.8% resistance), cefotaxime and ceftriaxone (approximate resistance&nbsp;11%).</p>
<p class="aj">Significant level of resistance was obtained for <i>K.pneumoniae</i> regarding all the antimicrobials tested except amikacin (9%&nbsp;resistance) and imipenem (0%&nbsp;resistance). Highest resistance rates of <i>Proteus</i> spp. strains were found to ampicilin, cefuroxime, piperacillin, amoxicillin/clavulanate and gentamicin. Imipenem was active against all the <i>Proteus</i> spp. isolates. Great efficacy was shown by ceftazidime (6.9% resistance) and amikacin (3.4% resistance) either. <i>Enterobacter</i> spp. strains were highly resistant to piperacillin and cefuroxime, the most active was imipenem (no resistant strains).</p>

<a name="table9"></a><br>
<p><b>Table 9.</b> Resistance (%) of nosocomial strains of <i>Enterobacteriaceae</i> (NPRS-3).</p>

<table class="brd" cellpadding="5" cellspacing="1" border="0" width="100%">
<tr class="bkg"><th>&nbsp;</th><th class="txc"><i>E.coli</i><br>(N=489)</th><th class="txc"><i>K.pneumoniae</i><br>(N=389)</th><th class="txc"><i>Proteus</i>&nbsp;spp.<br>(N=263)</th><th class="txc"><i>Enterobacter</i>&nbsp;spp.<br>(N=203)</th></tr>
<tr class="bkg"><td class="txt">Ampicillin</td><td class="txc">49.7</td><td class="txc">-</td><td class="txc">71.5</td><td class="txc">80.3</td></tr>
<tr class="bkg"><td class="txt">Piperacillin</td><td class="txc">40.9</td><td class="txc">68.4</td><td class="txc">37.6</td><td class="txc">44.8</td></tr>
<tr class="bkg"><td class="txt">Piperacillin/tazobactam</td><td class="txc">6.3</td><td class="txc">30.1</td><td class="txc">8.7</td><td class="txc">29.1</td></tr>
<tr class="bkg"><td class="txt">Amoxicillin/clavulanate</td><td class="txc">35.8</td><td class="txc">56.0</td><td class="txc">32.7</td><td class="txc">89.7</td></tr>
<tr class="bkg"><td class="txt">Cefuroxime</td><td class="txc">19.2</td><td class="txc">57.3</td><td class="txc">51.3</td><td class="txc">63.1</td></tr>
<tr class="bkg"><td class="txt">Cefotaxime</td><td class="txc">11.0</td><td class="txc">37.5</td><td class="txc">20.9</td><td class="txc">29.1</td></tr>
<tr class="bkg"><td class="txt">Ceftriaxone</td><td class="txc">11.5</td><td class="txc">40.4</td><td class="txc">17.5</td><td class="txc">30.5</td></tr>
<tr class="bkg"><td class="txt">Ceftazidime</td><td class="txc">7.8</td><td class="txc">33.7</td><td class="txc">6.9</td><td class="txc">24.6</td></tr>
<tr class="bkg"><td class="txt">Imipenem</td><td class="txc">0</td><td class="txc">0</td><td class="txc">0</td><td class="txc">0</td></tr>
<tr class="bkg"><td class="txt">Gentamicin</td><td class="txc">20.9</td><td class="txc">55.8</td><td class="txc">43.3</td><td class="txc">24.1</td></tr>
<tr class="bkg"><td class="txt">Amikacin</td><td class="txc">2.2</td><td class="txc">9.0</td><td class="txc">3.4</td><td class="txc">2.5</td></tr>
<tr class="bkg"><td class="txt">Ciprofloxacin</td><td class="txc">8.4</td><td class="txc">12.9</td><td class="txc">8.7</td><td class="txc">5.9</td></tr>
</table>

<a name="paeruginosa"></a><br>
<h4><i>Pseudomonas aeruginosa</i></h4>

<p class="aj">In NPRS-1997 multicenter study <i>P.aeruginosa</i> strains represented a very high level of resistance to gentamicin as well as to piperacillin, piperacillin/tazobactam and ciprofloxacin. As shown in <a href="#fig8">Figure&nbsp;8</a>, the most active against <i>P.aeruginosa</i> was amikacin (6.7% resistance) and ceftazidime (11.2% resistance).</p>

<a name="fig8"></a>
<table cellpadding="5" cellspacing="1" border="0" align="center"><tr><td>
<div align="center"><img src="modules/subjects/pages/eng/ar/images/arrus8en.gif" width="339" height="260" alt=""></div>
<p><b>Figure 8.</b>	Resistance (%) of <i>P.aeruginosa</i> nosocomial strains (NPRS-3)</p>
<p class="t8"><b>Abbreviations:</b><br> PIP - piperacillin; PTZ - piperacillin/tazobactam; CAZ - ceftazidime;<br> IMP - imipinem; GM - gentamicin; AMI - amikacin; CIP - ciprofloxacin.</p><br>
</td></tr></table>

<a name="acinetobacter"></a><br>
<h4><i>Acinetobacter</i> spp.</h4>

<p class="aj"><i>Acinetobacter</i>&nbsp;spp. strains isolated during the NPRS-3 survey (see <a href="#fig9">Figure&nbsp;9</a>) manifested the highest resistance to piperacillin, piperacillin/tazobactam, ceftazidime, gentamicin and ciprofloxacin. Imipenem and amikacin possessed the maximal activity (0% and 8.7% resistance correspondingly).</p>

<a name="fig9"></a>
<table cellpadding="5" cellspacing="1" border="0" align="center"><tr><td>
<div align="center"><img src="modules/subjects/pages/eng/ar/images/arrus9en.gif" width="338" height="274" alt=""></div>
<p><b>Figure 9.</b>	Resistance (%) of Acinetobacter spp. nosocomial strains (NPRS-3)</p>
<p class="t8"><b>Abbreviations:</b><br> PIP - piperacillin; PTZ - piperacillin/tazobactam; CAZ - ceftazidime;<br> IMP - imipinem; GM - gentamicin; AMI - amikacin; CIP - ciprofloxacin.</p>
</td></tr></table>

<p class="aj">Summarizing the results of NPRS-3 project it is worth to mention the significant rate of gram-negative pathogens resistance to ampicillin, amoxicillin/clavulanate, piperacillin, cefuroxime and gentamicin, while imipenem and amikacin were active against the majority of the strains tested.</p>
<p class="aj">In &laquo;Micromax&raquo; survey (see <a href="#table10">Table&nbsp;10</a>) performed in 1998 in 8 Moscow, Smolensk and Ekaterinburg hospitals low resistance rate was obtained among <i>E.coli</i> and <i>Proteus</i> spp. to &#946;-lactams with insignificant variations between different centres. At the same time high resistance of <i>Klebsiella</i> spp. to III&nbsp;generation cefalosporins was found (31-40%). This value regarding Cefepime was almost 2-fold lower - 16%. There was not found any <i>E.coli</i>, <i>Proteus</i> spp. or <i>K.pneumoniae</i> strains resistant to imipenem.</p>

<a name="table10"></a><br>
<p><b>Table 10.</b> Resistance (%) of nosocomial strains of <i>Enterobacteriaceae</i> (Micromax, 1999).</p>

<table class="brd" cellpadding="5" cellspacing="1" border="0" width="100%">
<tr class="bkg"><th class="txc">Antimicrobial</th><th class="txc"><i>E.coli</i></th><th class="txc"><i>Proteus</i>&nbsp;spp.</th><th class="txc"><i>Klebsiella</i>&nbsp;spp.</th></tr>
<tr class="bkg"><td class="txt">Piperacillin/tazobactam</td><td class="txc">3</td><td class="txc">1</td><td class="txc">17</td></tr>
<tr class="bkg"><td class="txt">Ceftriaxone</td><td class="txc">13</td><td class="txc">10</td><td class="txc">40</td></tr>
<tr class="bkg"><td class="txt">Ceftazidime</td><td class="txc">5</td><td class="txc">3</td><td class="txc">31</td></tr>
<tr class="bkg"><td class="txt">Cefepime</td><td class="txc">3</td><td class="txc">3</td><td class="txc">16</td></tr>
<tr class="bkg"><td class="txt">Imipenem</td><td class="txc">0</td><td class="txc">0</td><td class="txc">0</td></tr>
<tr class="bkg"><td class="txt">Ciprofloxacin</td><td class="txc">12</td><td class="txc">15</td><td class="txc">14</td></tr>
</table><br><br>

<h4><u>Sources</u></h4>
<ol class="txt">
<li>V.A.&nbsp;Kretchikov, A.V.&nbsp;Dekhnich, L.S.&nbsp;Stratchounski. Activity of linezolid against nosocomial strains of <i>Staphylococcus aureus</i> in Russia: results of multicenter study. In: 4th European Congress of Chemotherapy and Infection; 2002 May 4-7, Paris, France. International Journal of Antimicrobial Agents 2002; 19 Suppl 1; S94, Absrtact: PM221.</li>
<li>L.S.&nbsp;Stratchounski, A.V.&nbsp;Dekhnitch, Ju.A.&nbsp;Belkova. Susceptibility of <i>Staphylococcus aureus</i> from hospitalised patients topical antimicrobials in Russia. CMAC 2002; 4(2):157-63.</li>
<li>A.V.&nbsp;Dekhnich, I.A.&nbsp;Edelstain, A.D.&nbsp;Narezkina, G.E.&nbsp;Afinogenov, L.I.&nbsp;Akhmetova, L.G.&nbsp;Boronina, E.N.&nbsp;Gugutcidze, L.V.&nbsp;Gudkova, D.E.&nbsp;Zdzitovetcki, V.N.&nbsp;Ilyina, O.I.&nbsp;Kretchikova, N.E.&nbsp;Marusina, I.G.&nbsp;Multih, S.I.&nbsp;Pylaeva, I.V.&nbsp;Smirnov, T.N.&nbsp;Suborova, V.K.&nbsp;Taraban, N.M.&nbsp;Furletova, S.G.&nbsp;Hasanova, E.V.&nbsp;Schetinin, L.S.&nbsp;Stratchounski. Epidemiology of antimicrobial resistance of nosocomial strains of <i>Staphylococcus aureus</i> in Russia: results of prospective study. CMAC 2002; 4(4): 325-36.</li>
<li>A.&nbsp;Dekhnitch, O.&nbsp;Kretchikova, R.&nbsp;Kozlov, L.&nbsp;Stratchounski. Antibiotic resistance of enterococci isolated from premature born infants. In: European Congress of Chemotherapy; 1998 May 10-13, Hamburg, Germany. P.104. Abstract: T273.</li>
<li>L.&nbsp;Stratchounski, G.&nbsp;Reshedko, O.&nbsp;Stetsiouk, O.&nbsp;Kretchikova, E.&nbsp;Riabkova. Results of Russian country-wide surveillance of antimicrobial resistance of nosocomial gram-negative bacteria (ngnb) from 28 intensive care units (ICUs). In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19, Chicago, USA. P.113. Abstract: 67.</li>
<li>Sidorenko&nbsp;S.V., Strachunskii&nbsp;L.S., Akhmedova&nbsp;L.I., Beloborodov&nbsp;V.B., Bogomolova&nbsp;N.S., Bol'shakov&nbsp;L.V., Dekhnich&nbsp;A.V., Karabak&nbsp;V.I., Malikov&nbsp;V.E., Pavlova&nbsp;M.V., Polikarpova&nbsp;S.V., Rudnov&nbsp;V.A., Iakovlev&nbsp;V.P. The results of a multicenter study of the comparative activity of cefepime and other antibiotics against the causative agents of severe hospital infections (the Micromax program). Antibiot Khimioter. 1999; 44(11): 7-16.</li>
</ol>
<br><br>
<font class="note">The last modification date: 01 Mar 2004</font>
<br></td></tr></table></td></tr></table><hr><center><b>2004 &copy; &nbsp;Антибиотики и антимикробная терапия</b><br><a href="index.htm">http://antibiotic.ru/</a></center></center></td></tr></table></body>
</html></head></html>